Trial Profile
A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adult Subjects Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 10 Dec 2020 Primary endpoint (Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) 50 Copies/mL at Week 12 as Defined by Pure Virologic Response (PVR)) has been met, according to results published in the JAIDS
- 10 Dec 2020 Results published in the JAIDS
- 08 Aug 2019 Status changed from active, no longer recruiting to completed.